Presented at ACCESS CHINA Winter event 2020
July 31, 2021- ArcScan, Inc. announces the execution of a Stock Purchase Agreement with Shanghai Haohai Biological that will result in a $11.15 million Preferred Series B investment into ArcScan, Inc. ArcScan, Inc. will help Haohai further develop their rapidly expanding offering of implantable lenses.
Presented at ACCESS CHINA Summer event 2020
March 31, 2021- ImmuneOncia Therapeutics, Inc. signs exclusive license agreement with 3D Medicines, Inc. for the development, manufacture, and commercialization of IMC-002. The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China.
Presented at ACCESS CHINA Spring event 2020
November 18, 2020- AUM Biosciences and Newsoara Biopharma announce a 5-year transformational Strategic Partnership to co-develop and co-discover Next-Generation Cancer Therapeutics. AUM will license exclusive greater China rights of AUM001, AUM302 and AUM003, and up to a further 3 candidates for a maximum of 6 oncology drugs.
Presented at ACCESS CHINA Spring event 2020
March 1, 2021- Starton Therapeutics entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ in Mainland China with Haisco Pharma. STAR-OLZ is a once-weekly transdermal delivery system for chemotherapy induced nausea and vomiting and PARP inhibitor induced nausea and vomiting.
Presented at ACCESS CHINA Spring event 2020
October 31, 2020- Rhizen Pharmaceuticals signs exclusive license agreement with Curon Biopharma for the development and commercialization of Tenalisib in Greater China. Tenalisib (RP6530) is a highly selective, next-generation, orally active, dual PI3K delta and gamma inhibitor, that is currently in Phase 2 clinical development for hematological malignancies.
BioToChina.org 